Synthetic peptide, and cosmetic composition or pharmaceutical composition and application thereof
US-2024352069-A1 · Oct 24, 2024 · US
US2017143628A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017143628-A1 |
| Application number | US-201615355225-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 18, 2016 |
| Priority date | Nov 25, 2015 |
| Publication date | May 25, 2017 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present application relates to a micelle comprising a drug encapsulated by an amphiphilic polymer and a composition comprising the same. The micelle of the present application has an excellent dispersion property on an aqueous solution and a superior percutaneous absorption characteristic on preparing a formulation.
Opening claim text (preview).
What is claimed is: 1 . A micelle comprising: a drug; and an amphiphilic polymer which encapsulates said drug, has a first block (A) and a second block (B) that is phase-separated with said first block (A) and comprises a polymerization unit (B1) of an acrylic monomer or a vinylic monomer having a solubility parameter of a single polymer of less than 10.0 (cal/cm 3 ) 1/2 and a polymerization unit (B2) of a polymerizable monomer having a functional group being capable of forming a hydrogen bond, wherein a weight ratio (B1:B2) of the polymerization unit (B1) of an acrylic monomer or a vinylic monomer having a solubility parameter of a single polymer of less than 10.0 (cal/cm 3 ) 1/2 and the polymerization unit (B2) of a polymerizable monomer having a functional group being capable of forming a hydrogen bond, in the second block (B), is in a range of 1:9 to 9:1. 2 . The micelle according to claim 1 , wherein the drug comprises a physiologically active substance. 3 . The micelle according to claim 2 , wherein the physiologically active substance is sparingly soluble. 4 . The micelle according to claim 3 , wherein the sparingly soluble and physiologically active substance is any one selected from the group consisting of genistein, daidzein, cucurbitasin, prangenidin or a derivative thereof; a polyphenol; or a mixture thereof. 5 . The micelle according to claim 4 , wherein the sparingly soluble and physiologically active substance is genistein or a glycoside of said genistein. 6 . The micelle according to claim 1 , wherein the first block (A) comprises a polymer having a solubility parameter of 10 (cal/cm 3 ) 1/2 or more. 7 . The micelle according to claim 6 , wherein the first block (A) is any one selected from the group consisting of polyethylene glycol, a polyethylene glycol-propylene glycol copolymer, polyvinyl pyrrolidone and polyethyleneimine. 8 . The micelle according to claim 1 , wherein the acrylic monomer is represented by Formula 1 or Formula 2 below: where, Q in Formula 1 and 2 is hydrogen or an alkyl group, B in Formula 1 is a straight or branched alkyl group having at least one carbon atom, an alicyclic hydrocarbon group, an aromatic substituent or a carboxyl group, and R 1 and R 2 in Formula 2 are each independently hydrogen, a straight or branched alkyl group having at least one carbon atom, an alicyclic hydrocarbon group, or an aromatic substituent. 9 . The micelle according to claim 8 , wherein Q in Formula 1 is hydrogen or an alkyl group having 1 to 4 carbon atoms, B is an alkyl group having at least one carbon atom or an alicyclic hydrocarbon group having 6 to 12 carbon atoms. 10 . The micelle according to claim 1 , wherein the vinylic monomer is represented by Formula 3 or Formula 4 below: where, X is a nitrogen atom or an oxygen atom, Y is a carbonyl group or a single bond, R 3 and R 5 are each independently hydrogen or an alkyl group, or R 3 and R 5 are linked together to form an alkylene group, and R 4 is an alkenyl group (provided that R 3 is not present, if X is an oxygen atom); where, R 6 , R 7 and R 8 are each independently hydrogen or an alkyl group, and R 9 is a cyano group or an aromatic substituent. 11 . The micelle according to claim 1 , wherein the functional group is a hydroxyl group, an amine group, a nitro group, an amino group, an imide group, an alkoxysilane group or a cyano group. 12 . The micelle according to claim 1 , wherein the amphiphilic polymer has a block ratio (A:B) of the first block (A) and the second block (B) different from each other. 13 . The micelle according to claim 12 , wherein the block ratio (A:B) of the first block (A) and the second block (B) in the amphiphilic polymer is 1:9 to 9:1. 14 . The micelle according to claim 1 , wherein the block ratio (A:B) of the first block (A) and the second block (B) in the amphiphilic polymer is 3:7 to 7:3. 15 . The micelle according to claim 1 , wherein the second block of the amphiphilic polymer is adjacent to the drug. 16 . The micelle according to claim 1 , wherein the average particle diameter is in a range of 1 to 10,000 nm. 17 . A composition for preparing particles comprising the micelle of claim 1 . 18 . A pharmaceutical or cosmetic composition comprising the micelle of claim 1 . 19 . The pharmaceutical or cosmetic composition according to claim 18 , wherein the composition is in a water-in-oil type emulsion form or an oil-in-water type emulsion form. 20 . A process for preparing the micelle of claim 1 comprising: a step of polymerizing a polymer forming a first block (A) and an acrylic monomer or a vinylic monomer having a solubility parameter of a single polymer of less than 10.0 (cal/cm 3 ) 1/2 to prepare an amphiphilic polymer; and a step of mixing said amphiphilic polymer and a drug.
condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)} · CPC title
Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title
Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title
Preparations for care of the skin · CPC title
Emulsions · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.